Palvella Therapeutics, Inc.
General ticker "PVLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Palvella Therapeutics, Inc. follows the US Stock Market performance with the rate: 48.9%.
Estimated limits based on current volatility of 2.9%: low 129.98$, high 137.80$
Factors to consider:
- Total employees count: 29 (+107.1%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Current price 25.7% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [34.92$, 105.38$]
- 2026-12-31 to 2027-12-31 estimated range: [18.00$, 59.59$]
Short-term PVLA quotes
Long-term PVLA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $42.81MM | $0.00MM | $0.00MM |
| Operating Expenses | $72.57MM | $14.10MM | $38.60MM |
| Operating Income | $-29.76MM | $-14.10MM | $-38.60MM |
| Non-Operating Income | $5.21MM | $-3.34MM | $-3.11MM |
| Interest Expense | $0.00MM | $0.43MM | $0.00MM |
| R&D Expense | $8.79MM | $8.15MM | $22.84MM |
| Income(Loss) | $-24.54MM | $-17.43MM | $-41.72MM |
| Net Income(Loss)* | $-24.54MM | $-17.43MM | $-41.72MM |
| Stockholders Equity | $26.76MM | $62.61MM | $27.98MM |
| Assets | $38.68MM | $88.23MM | $59.56MM |
| Operating Cash Flow | $-13.70MM | $-10.84MM | $-25.01MM |
| Financing Cash Flow | $5.00MM | $87.09MM | $-0.66MM |
| Earnings Per Share** | $-19.36 | $-7.83 | $-3.71 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.